The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein inhibitors, and their roles in bone repair and regeneration

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Fan, Lihong ^a   Li, Jia ^a   Yu, Zefeng ^a   Dang, Xiaoqian ^a   Wang, Kunzheng ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; VASCULOTROPIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; PROLYL HYDROXYLASE INHIBITOR;

ANGIOGENESIS; BONE DEVELOPMENT; BONE MASS; BONE REGENERATION; BONE REMODELING; BONE TUMOR; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DISTRACTION OSTEOGENESIS; FRACTURE; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOPOROSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BONE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE AND BONES; BONE DEVELOPMENT; BONE REGENERATION; HUMANS; PROLYL HYDROXYLASES; PROLYL-HYDROXYLASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84901801677     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/239356     Document Type: Review

References (99)

1. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., Poellinger L., Fujii-Kuriyama Y., Molecular mechanisms of transcription activation by HLF and HIF1 α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. The EMBO Journal 1999 18 7 1905 1914 2-s2.0-0033118983 (Pubitemid 29158534)
2. Nangaku M., Izuhara Y., Takizawa S., Yamashita T., Fujii-Kuriyama Y., Ohneda O., Yamamoto M., Van Ypersele De Strihou C., Hirayama N., Miyata T., A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 12 2548 2554 2-s2.0-36348999185 10.1161/ATVBAHA.107.148551 (Pubitemid 350158904)
3. Barth S., Nesper J., Hasgall P. A., Wirthner R., Nytko K. J., Edlich F., Katschinski D. M., Stiehl D. P., Wenger R. H., Camenisch G., The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Molecular and Cellular Biology 2007 27 10 3758 3768 2-s2.0-34248199954 10.1128/MCB.01324-06 (Pubitemid 46726183)
4. Danis A., Mechanism of bone lengthening by the Ilizarov technique. Bulletin et Memoires de lAcademie Royale de Medecine de Belgique 2001 156 1-2 107 112 2-s2.0-0035225713
5. Wang G. L., Jiang B.-H., Semenza G. L., Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochemical and Biophysical Research Communications 1995 216 2 669 675 2-s2.0-0028785860 10.1006/bbrc.1995.2674
6. Li H., Ko H. P., Whitlock J. P. Jr., Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1 α Journal of Biological Chemistry 1996 271 35 21262 21267 2-s2.0-0029788974 10.1074/jbc.271.35.21262 (Pubitemid 26292983)
7. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 2-s2.0-0142166332 (Pubitemid 37328811)
8. Hon W.-C., Wilson M. I., Harlos K., Claridge T. D. W., Schofield C. J., Pugh C. W., Maxwell P. R., Ratcliffe P. J., Stuart D. I., Jones E. Y., Structural basis for the recognition of hydroxyproline in HIF-1 α by pVHL. Nature 2002 417 6892 975 978 2-s2.0-18444368709 10.1038/nature00767 (Pubitemid 34716877)
9. Min J.-H., Yang H., Ivan M., Gertler F., Kaelin W. G. Jr., Pavietich N. P., Structure of an HIF-1 α -pVHL complex: hydroxyproline recognition in signaling. Science 2002 296 5574 1886 1889 2-s2.0-0037035851 10.1126/science.1073440 (Pubitemid 34596278)
10. 2 sensing. Science 2001 292 5516 464 468 2-s2.0-0035917313 (Pubitemid 32335941)
11. 2-regulated prolyl hydroxylation. Science 2001 292 5516 468 472 2-s2.0-0035917808 (Pubitemid 32335942)
12. Masson N., Willam C., Maxwell P. H., Pugh C. W., Ratcliffe P. J., Independent function of two destruction domains in hypoxia-inducible factor- α chains activated by prolyl hydroxylation. The EMBO Journal 2001 20 18 5197 5206 2-s2.0-0035903468 10.1093/emboj/20.18.5197 (Pubitemid 32910914)
13. Maxwell P. H., Wlesener M. S., Chang G.-W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999 399 6733 271 275 2-s2.0-0033587146 10.1038/20459 (Pubitemid 29246458)
14. Ohh M., Park C. W., Ivan M., Hoffman M. A., Kim T.-Y., Huang L. E., Pavletich N., Chau V., Kaelin W. G., Ubiquitination of hypoxia-inducible factor requires direct binding to the β -domain of the von Hippel-lindau protein. Nature Cell Biology 2000 2 7 423 427 2-s2.0-0033776536 10.1038/35017054
15. Hirsilä M., Koivunen P., Günzler V., Kivirikko K. I., Myllyharju J., Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. Journal of Biological Chemistry 2003 278 33 30772 30780 2-s2.0-0043234538 10.1074/jbc.M304982200 (Pubitemid 36994584)
16. Sang N., Fang J., Srinivas V., Leshchinsky I., Caro J., Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 α is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Molecular and Cellular Biology 2002 22 9 2984 2992 2-s2.0-0036232662 10.1128/MCB.22.9.2984-2992.2002 (Pubitemid 34437457)
17. Arany Z., Huang L. E., Eckner R., Bhattacharya S., Jiang C., Goldberg M. A., Bunn H. F., Livingston D. M., An essential role for p300/CBP in the cellular response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 1996 93 23 12969 12973 2-s2.0-0029803552 10.1073/pnas.93.23.12969 (Pubitemid 26382753)
18. Wenger R. H., Stiehl D. P., Camenisch G., Integration of oxygen signaling at the consensus HRE. Science's STKE 2005 2005 306, article re12 2-s2.0-31444444162
19. Koivunen P., Tiainen P., Hyvärinen J., Williams K. E., Sormunen R., Klaus S. J., Kivirikko K. I., Myllyharju J., An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor α Journal of Biological Chemistry 2007 282 42 30544 30552 2-s2.0-35648930417 10.1074/jbc.M704988200 (Pubitemid 350035186)
20. Epstein A. C. R., Gleadle J. M., McNeill L. A., Hewitson K. S., O'Rourke J., Mole D. R., Mukherji M., Metzen E., Wilson M. I., Dhanda A., Tian Y.-M., Masson N., Hamilton D. L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P. H., Pugh C. W., Schofield C. J., Ratcliffe P. J., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001 107 1 43 54 2-s2.0-17944375360 10.1016/S0092-8674(01) 00507-4 (Pubitemid 32972036)
21. Appelhoffl R. J., Tian Y.-M., Raval R. R., Turley H., Harris A. L., Pugh C. W., Ratcliffe P. J., Gleadle J. M., Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. Journal of Biological Chemistry 2004 279 37 38458 38465 2-s2.0-4644318828 10.1074/jbc.M406026200 (Pubitemid 39295997)
22. Metzen E., Stiehl D. P., Doege K., Marxsen J. H., Hellwig-Bürgel T., Jelkmann W., Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochemical Journal 2005 387 3 711 717 2-s2.0-18844408840 10.1042/BJ20041736 (Pubitemid 40685705)
23. Pescador N., Cuevas Y., Naranjo S., Alcaide M., Villar D., Landázuri M. O., Del Peso L., Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochemical Journal 2005 390 1 189 197 2-s2.0-23944454868 10.1042/BJ20042121 (Pubitemid 41192244)
24. Marxsen J. H., Stengel P., Doege K., Heikkinen P., Jokilehto T., Wagner T., Jelkmann W., Jaakkola P., Metzen E., Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF- α -prolyl-4-hydroxylases. Biochemical Journal 2004 381 3 761 767 2-s2.0-4344645563 10.1042/BJ20040620 (Pubitemid 39120486)
25. D'Angelo G., Duplan E., Boyer N., Vigne P., Frelin C., Hypoxia up-regulates prolyl hydroxylase activity. A feedback mechansim that limits HIF-1 responses during reoxygenation. Journal of Biological Chemistry 2003 278 40 38183 38187 2-s2.0-0141643358 10.1074/jbc.M302244200 (Pubitemid 37221706)
26. Stiehl D. P., Wirthner R., Köditz J., Spielmann P., Camenisch G., Wenger R. H., Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels: evidence for an autoregulatory oxygen-sensing system. Journal of Biological Chemistry 2006 281 33 23482 23491 2-s2.0-33747660292 10.1074/jbc.M601719200 (Pubitemid 44274123)
27. Schofield C. J., Ratcliffe P. J., Oxygen sensing by HIF hydroxylases. Nature Reviews Molecular Cell Biology 2004 5 5 343 354 2-s2.0-2342644926 10.1038/nrm1366 (Pubitemid 38579472)
28. Hill P., Shukla D., Tran M. G. B., Aragones J., Cook H. T., Carmeliet P., Maxwell P. H., Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. Journal of the American Society of Nephrology 2008 19 1 39 46 2-s2.0-38149075003 10.1681/ASN.2006090998
29. Eckle T., Kohler D., Lehmann R., Kasmi K. C. E., Eltzschig H. K., Hypoxia-inducible factor-1 is central to cardioprotection a new paradigm for ischemic preconditioning. Circulation 2008 118 2 166 175 2-s2.0-47649128513 10.1161/CIRCULATIONAHA.107.758516
30. Cummins E. P., Seeballuck F., Keely S. J., Mangan N. E., Callanan J. J., Fallon P. G., Taylor C. T., The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008 134 1 156 165 2-s2.0-37349118314 10.1053/j.gastro.2007.10.012 (Pubitemid 350309317)
31. Safran M., Kim W. Y., O'Connell F., Flippin L., Günzler V., Horner J. W., DePinho R. A., Kaelin W. G. Jr., Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proceedings of the National Academy of Sciences of the United States of America 2006 103 1 105 110 2-s2.0-30444445382 10.1073/pnas.0509459103 (Pubitemid 43076112)
32. Yan L., Colandrea V. J., Hale J. J., Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opinion on Therapeutic Patents 2010 20 9 1219 1245 2-s2.0-77955790529 10.1517/13543776.2010.510836
33. Schneider C., Krischke G., Keller S., Walkinshaw G., Arend M., Rascher W., Gassmann M., Trollmann R., Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain. Brain Research 2009 1280 43 51 2-s2.0-67649439143 10.1016/j.brainres.2009.05.023
34. Rosenberger C., Rosen S., Shina A., Frei U., Eckardt K.-U., Flippin L. A., Arend M., Klaus S. J., Heyman S. N., Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrology Dialysis Transplantation 2008 23 11 3472 3478 2-s2.0-54149114944 10.1093/ndt/gfn276
35. Bao W., Qin P., Needle S., Erickson-Miller C. L., Duffy K. J., Ariazi J. L., Zhao S., Olzinski A. R., Behm D. J., Teg Pipes G. C., Jucker B. M., Hu E., Lepore J. J., Willette R. N., Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. Journal of Cardiovascular Pharmacology 2010 56 2 147 155 2-s2.0-77955982949 10.1097/FJC.0b013e3181e2bfef
36. Hopfer U., Hopfer H., Jablonski K., Stahl R. A. K., Wolf G., The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3). Journal of Biological Chemistry 2006 281 13 8645 8655 2-s2.0-33646852807 10.1074/jbc.M513751200 (Pubitemid 43847969)
37. Claesson-Welsh L., Welsh M., VEGFA and tumour angiogenesis. Journal of Internal Medicine 2013 273 2 114 127
38. Li Y.-X., Ding S.-J., Xiao L., Guo W., Zhan Q., Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 α and erythropoietin. Neuroscience Bulletin 2008 24 2 89 95 2-s2.0-44349181985 10.1007/s12264-008- 0089-3 (Pubitemid 351738284)
39. Hishikawa T., Ono S., Ogawa T., Tokunaga K., Sugiu K., Date I., Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. Neurosurgery 2008 62 1 232 240 2-s2.0-41749119704 10.1227/01.NEU.0000311082.88766.33
40. Shen X., Wan C., Ramaswamy G., Mavalli M., Wang Y., Duvall C. L., Lian F. D., Guldberg R. E., Eberhart A., Clemens T. L., Gilbert S. R., Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. Journal of Orthopaedic Research 2009 27 10 1298 1305 2-s2.0-70349220913 10.1002/jor.20886
41. Stewart R., Goldstein J., Eberhardt A., Gabriel Chu G. T.-M., Gilbert S., Increasing vascularity to improve healing of a segmental defect of the rat femur. Journal of Orthopaedic Trauma 2011 25 8 472 476 2-s2.0-80051544017 10.1097/BOT.0b013e31822588d8
42. Zhang W., Li G., Deng R., Deng L., Qiu S., New bone formation in a true bone ceramic scaffold loaded with desferrioxamine in the treatment of segmental bone defect: a preliminary study. Journal of Orthopaedic Science 2012 17 3 289 298 2-s2.0-84859464499 10.1007/s00776-012-0206-z
43. Wan C., Gilbert S. R., Wang Y., Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proceedings of the National Academy of Sciences of the United States of America 2008 105 2 686 691 10.1073/pnas.0708474105 (Pubitemid 351171769)
44. Donneys A., Deshpande S. S., Tchanque-Fossuo C. N., Deferoxamine expedites consolidation during mandibular distraction osteogenesis. Bone 2013 55 2 384 390 10.1016/j.bone.2013.04.005
45. Xi L., Taher M., Yin C., Salloum F., Kukreja R. C., Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1 α and AP-1 and iNOS signaling. American Journal of Physiology-Heart and Circulatory Physiology 2004 287 6 H2369 H2375 2-s2.0-9344262366 10.1152/ajpheart.00422.2004 (Pubitemid 39557104)
46. Philipp S., Cui L., Ludolph B., Kelm M., Schulz R., Cohen M. V., Downey J. M., Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS. American Journal of Physiology-Heart and Circulatory Physiology 2006 290 1 H450 H457 2-s2.0-33644790434 10.1152/ajpheart.00472.2005
47. Hsieh M. M., Linde N. S., Wynter A., Metzger M., Wong C., Langsetmo I., Lin A., Smith R., Rodgers G. P., Donahue R. E., Klaus S. J., Tisdale J. F., HIF-prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007 110 6 2140 2147 2-s2.0-34548829081 10.1182/blood-2007-02- 073254 (Pubitemid 47443933)
48. Zhao Q., Shen X., Zhang W., Zhu G., Qi J., Deng L., Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss. Bone 2012 50 3 763 770 2-s2.0-84856957381 10.1016/j.bone.2011.12.003
49. Wang Y., Wan C., Gilbert S. R., Clemens T. L., Oxygen sensing and osteogenesis. Annals of the New York Academy of Sciences 2007 1117 1 11 (Pubitemid 350191282)
50. Rios C. N., Skoracki R. J., Mathur A. B., GNAS1 and PHD2 short-interfering RNA support bone regeneration in vitro and in an in vivo sheep model. Clinical Orthopaedics and Related Research 2012 470 9 2541 2553
51. Natarajan R., Salloum F. N., Fisher B. J., Kukreja R. C., Fowler A. A. III, Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circulation Research 2006 98 1 133 140 2-s2.0-33644837102 10.1161/01.RES.0000197816.63513.27 (Pubitemid 43970213)
52. Czibik G., Gravning J., Martinov V., Ishaq B., Knudsen E., Attramadal H., Valen G., Gene therapy with hypoxia-inducible factor 1 alpha in skeletal muscle is cardioprotective in vivo. Life Sciences 2011 88 11-12 543 550 2-s2.0-79952438784 10.1016/j.lfs.2011.01.006
53. Date T., Mochizuki S., Belanger A. J., Yamakawa M., Luo Z., Vincent K. A., Cheng S. H., Gregory R. J., Jiang C., Expression of constitutively stable hybrid hypoxia-inducible factor-1 α protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. American Journal of Physiology-Cell Physiology 2005 288 2 C314 C320 2-s2.0-12144257637 10.1152/ajpcell.00374.2004 (Pubitemid 40105342)
54. Tothill P., MacPherson J. N., The distribution of blood flow to the whole skeleton in dogs, rabbits and rats measured with microspheres. Clinical Physics and Physiological Measurement 1986 7 2 117 123 2-s2.0-0022716301 10.1088/0143-0815/7/2/002 (Pubitemid 16017976)
55. Gross P. M., Heistad D. D., Marcus M. L., Neurohumoral regulation of blood flow to bones and marrow. The American Journal of Physiology 1979 237 4 H440 H448 2-s2.0-0018534022 (Pubitemid 10249646)
56. Riddle R. C., Khatri R., Schipani E., Clemens T. L., Role of hypoxia-inducible factor-1 α in angiogenic-osteogenic coupling. Journal of Molecular Medicine 2009 87 6 583 590 2-s2.0-67349123805 10.1007/s00109-009- 0477-9
57. Semenza G. L., Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Seminars in Cancer Biology 2009 19 1 12 16 2-s2.0-60549083256 10.1016/j.semcancer.2008.11.009
58. Schipani E., Ryan H. E., Didrickson S., Kobayashi T., Knight M., Johnson R. S., Hypoxia in cartilage: HIF-1 α is essential for chondrocyte growth arrest and survival. Genes and Development 2001 15 21 2865 2876 2-s2.0-0035499204 (Pubitemid 33042056)
59. Wang Y., Wan C., Deng L., Liu X., Cao X., Gilbert S. R., Bouxsein M. L., Faugere M.-C., Guldberg R. E., Gerstenfeld L. C., Haase V. H., Johnson R. S., Schipani E., Clemens T. L., The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal development. Journal of Clinical Investigation 2007 117 6 1616 1626 2-s2.0-34249913494 10.1172/JCI31581 (Pubitemid 46871346)
60. Tsai C. C., Yew T. L., Yang D. C., Huang W. H., Hung S. C., Benefits of hypoxic culture on bone marrow multipotent stromal cells. American Journal of Blood Research 2012 2 3 148 159
61. Tsai C.-C., Chen Y.-J., Yew T.-L., Chen L.-L., Wang J.-Y., Chiu C.-H., Hung S.-C., Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011 117 2 459 469 2-s2.0-78751535908 10.1182/blood-2010-05-287508
62. Hung S.-C., Pochampally R. R., Hsu S.-C., Sanchez C. C., Chen S.-C., Spees J., Prockop D. J., Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS ONE 2007 2 5, article e416 2-s2.0-34548739439 10.1371/journal.pone. 0000416
63. Okuyama H., Krishnamachary B., Zhou Y. F., Nagasawa H., Bosch-Marce M., Semenza G. L., Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. Journal of Biological Chemistry 2006 281 22 15554 15563 2-s2.0-33744959141 10.1074/jbc.M602003200 (Pubitemid 43855148)
64. Fehrer C., Brunauer R., Laschober G., Unterluggauer H., Reitinger S., Kloss F., Gülly C., Gaßner R., Lepperdinger G., Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell 2007 6 6 745 757 2-s2.0-36249020427 10.1111/j.1474-9726.2007.00336.x (Pubitemid 350131043)
65. Holzwarth C., Vaegler M., Gieseke F., Pfister S. M., Handgretinger R., Kerst G., Müller I., Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biology 2010 11, article 11 2-s2.0-77349087595 10.1186/1471-2121-11-11
66. Yang D.-C., Yang M.-H., Tsai C.-C., Huang T.-F., Chen Y.-H., Hung S.-C., Hypoxia inhibits osteogenesis in human mesenchymal stem cells through direct regulation of RUNX2 by TWIST. PLoS ONE 2011 6 9 2-s2.0-80052560423 10.1371/journal.pone.0023965 e23965
67. Lord-Dufour S., Copland I. B., Levros L.-C. Jr., Post M., Das A., Khosla C., Galipeau J., Rassart E., Annabi B., Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1 α: targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. Stem Cells 2009 27 3 489 497 2-s2.0-65249185690 10.1634/stemcells.2008-0855
68. Penna C., Perrelli M.G., Karam J. P., Pharmacologically active microcarriers influence VEGF-A effects on mesenchymal stem cell survival. Journal of Cellular and Molecular Medicine 2013 17 1 192 204
69. Chen B., Song Y.-B., Li Y.-H., Pei G.-X., Effect of vascular endothelial growth factor gene transfer on proliferation and metabolism of human bone marrow stromal cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2008 28 7 1172 1175 2-s2.0-64149087237
70. Fiedler J., Leucht F., Waltenberger J., Dehio C., Brenner R. E., VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochemical and Biophysical Research Communications 2005 334 2 561 568 2-s2.0-22144446006 10.1016/j.bbrc.2005.06.116 (Pubitemid 40982403)
71. Lin H., Shabbir A., Molnar M., Yang J., Marion S., Canty J. M. Jr., Lee T., Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells. Journal of Cellular Physiology 2008 216 2 458 468 2-s2.0-46049099374 10.1002/jcp.21414 (Pubitemid 351898474)
72. Huang Z., Ren P.-G., Ma T., Smith R. L., Goodman S. B., Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Cytokine 2010 51 3 305 310 2-s2.0-77955281178 10.1016/j.cyto.2010.06.002
73. Liu Y., Berendsen A. D., Jia S., Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. The Journal of Clinical Investigation 2012 122 9 3101 3113 10.1172/JCI61209
74. Midy V., Plouet J., Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochemical and Biophysical Research Communications 1994 199 1 380 386 2-s2.0-0028237788 10.1006/bbrc.1994.1240 (Pubitemid 24179960)
75. Mayr-wohlfart U., Waltenberger J., Hausser H., Kessler S., Günther K.-P., Dehio C., Puhl W., Brenner R. E., Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002 30 3 472 477 2-s2.0-0036192486 10.1016/S8756-3282(01)00690-1 (Pubitemid 34204121)
76. Gruber R., Kandler B., Holzmann P., Vögele-Kadletz M., Losert U., Fischer M. B., Watzek G., Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Engineering 2005 11 5-6 896 903 2-s2.0-21844438464 10.1089/ten.2005.11.896 (Pubitemid 40960792)
77. Potapova I. A., Gaudette G. R., Brink P. R., Robinson R. B., Rosen M. R., Cohen I. S., Doronin S. V., Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 2007 25 7 1761 1768 2-s2.0-34547187820 10.1634/stemcells. 2007-0022 (Pubitemid 47121855)
78. Thebaud N. B., Whatever their differentiation status, human progenitor derived-or mature-endothelial cells induce osteoblastic differentiation of bone marrow stromal cells. Journal of Tissue Engineering and Regenerative Medicine 2012 6 10 e51 e60 10.1002/term.1539
79. Gerstenfeld L. C., Cullinane D. M., Barnes G. L., Graves D. T., Einhorn T. A., Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. Journal of Cellular Biochemistry 2003 88 5 873 884 2-s2.0-0037376627 10.1002/jcb.10435 (Pubitemid 36337032)
80. Al-Aql Z. S., Alagl A. S., Graves D. T., Gerstenfeld L. C., Einhorn T. A., Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. Journal of Dental Research 2008 87 2 107 118 2-s2.0-39149143035 10.1177/154405910808700215
81. Choi I. H., Ahn J. H., Chung C. Y., Cho T.-J., Vascular proliferation and blood supply during distraction osteogenesis: a scanning electron microscopic observation. Journal of Orthopaedic Research 2000 18 5 698 705 2-s2.0-0034264874
82. Komatsu D. E., Hadjiargyrou M., Activation of the transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair. Bone 2004 34 4 680 688 2-s2.0-1642333512 10.1016/j.bone.2003.12.024 (Pubitemid 38393804)
83. Ferguson C., Alpern E., Miclau T., Helms J. A., Does adult fracture repair recapitulate embryonic skeletal formation? Mechanisms of Development 1999 87 1-2 57 66 2-s2.0-0032841147 10.1016/S0925-4773(99)00142-2 (Pubitemid 29428086)
84. Le A. X., Miclau T., Hu D., Helms J. A., Molecular aspects of healing in stabilized and non-stabilized fractures. Journal of Orthopaedic Research 2001 19 1 78 84 2-s2.0-0035075677 10.1016/S0736-0266(00)00006-1 (Pubitemid 32288639)
85. Street J., Bao M., DeGuzman L., Bunting S., Peale F. V. Jr., Ferrara N., Steinmetz H., Hoeffel J., Cleland J. L., Daugherty A., Van Bruggen N., Redmond H. P., Carano R. A. D., Filvaroff E. H., Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proceedings of the National Academy of Sciences of the United States of America 2002 99 15 9656 9661 2-s2.0-0037162547 10.1073/pnas.152324099 (Pubitemid 34831103)
86. Tarkka T., Sipola A., Jämsä T., Soini Y., Ylä-Herttuala S., Tuukkanen J., Hautala T., Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. Journal of Gene Medicine 2003 5 7 560 566 2-s2.0-0344289637 10.1002/jgm.392 (Pubitemid 40310399)
87. Geiger F., Bertram H., Berger I., Lorenz H., Wall O., Eckhardt C., Simank H.-G., Richter W., Vascular endothelial growth factor gene-activated matrix (VEGF 165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. Journal of Bone and Mineral Research 2005 20 11 2028 2035 2-s2.0-27444447463 10.1359/JBMR.050701 (Pubitemid 41532788)
88. Huang Y.-C., Kaigler D., Rice K. G., Krebsbach P. H., Mooney D. J., Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. Journal of Bone and Mineral Research 2005 20 5 848 857 2-s2.0-17644374486 10.1359/JBMR.041226 (Pubitemid 40571642)
89. Liu X.-D., Deng L.-F., Wang J., Qi J., Zhou Q., Wang J.-S., Wei L., Zhu Y.-P., Clemens T., The regulation of hypoxia inducible factor-1alpha on osteoblast function in postmenopausal osteoporosis. Zhonghua Wai Ke Za Zhi 2007 45 18 1274 1278 2-s2.0-54049087024
90. Ilizarov G. A., Clinical application of the tension-stress effect for limb lengthening. Clinical Orthopaedics and Related Research 1990 250 8 26 2-s2.0-0025073322 (Pubitemid 20033960)
91. Jacobsen K. A., Al-Aql Z. S., Wan C., Fitch J. L., Stapleton S. N., Mason Z. D., Cole R. M., Gilbert S. R., Clemens T. L., Morgan E. F., Einhorn T. A., Gerstenfeld L. C., Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. Journal of Bone and Mineral Research 2008 23 5 596 609 2-s2.0-42449132519 10.1359/jbmr.080103 (Pubitemid 351575014)
92. He J. F., Xie Z. J., Zhao H., Ge W. L., Hu J. A., Li Y. N., Gu Z. Y., Immunohistochemical and in-situ hybridization study of hypoxia inducible factor-1 α and angiopoietin-1 in a rabbit model of mandibular distraction osteogenesis. International Journal of Oral and Maxillofacial Surgery 2008 37 6 554 560 2-s2.0-44249092532 10.1016/j.ijom.2008.01.015 (Pubitemid 351726421)
93. Pacicca D. M., Patel N., Lee C., Salisbury K., Lehmann W., Carvalho R., Gerstenfeld L. C., Einhorn T. A., Expression of angiogenic factors during distraction osteogenesis. Bone 2003 33 6 889 898 2-s2.0-0346996353 10.1016/j.bone.2003.06.002 (Pubitemid 37543565)
94. Yang Y., Sun M., Wang L., Jiao B., HIFs, angiogenesis, and cancer. Journal of Cellular Biochemistry 2013 114 5 967 974
95. Hickey M. M., Simon M. C., Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Current Topics in Developmental Biology 2006 76 217 257 2-s2.0-33751192872 10.1016/S0070-2153(06)76007-0 (Pubitemid 44773777)
96. Ryan H. E., Lo J., Johnson R. S., HIF-1 α is required for solid tumor formation and embryonic vascularization. The EMBO Journal 1998 17 11 3005 3015 2-s2.0-0032100732 10.1093/emboj/17.11.3005 (Pubitemid 28254373)
97. Yang Q. C., Zeng B. F., Shi Z. M., Dong Y., Jiang Z. M., Huang J., Lv Y. M., Yang C. X., Liu Y. W., Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. Journal of Experimental and Clinical Cancer Research 2006 25 4 593 599 2-s2.0-33846625170 (Pubitemid 46170683)
98. Wu Q., Yang S.-H., Wang R.-Y., Ye S.-N., Xia T., Ma D.-Z., Effect of silencing HIF-1alpha by RNA interference on expression of vascular endothelial growth factor in osteosarcoma cell line SaOS-2 under hypoxia. Chinese Journal of Cancer 2005 24 5 531 535 2-s2.0-33846436473
99. Wu Q., Yang S.-H., Ye S.-N., Wang R.-Y., Therapeutic effects of RNA interference targeting HIF-1 alpha gene on human osteosarcoma. Zhonghua Yi Xue Za Zhi 2005 85 6 409 413 2-s2.0-14844300839 (Pubitemid 40347635)